09/11/2018 15:04:10

Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group

DALLAS, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications, presented initial data from its Phase 2 trial for Ewing’s sarcoma at the 2018 Annual Meeting of Children’s Oncology Group (COG).

This is a two-part open-label, non-randomized, single-arm Phase 2 study in patients with recurrent or refractory Ewing’s Sarcoma. Part 2 of the study was established in order to assess safety and efficacy of Temozolomide / Irinotecan in combination with Vigil. All patients included in the study signed informed consent for tissue procurement treatment on the study according to the requirements of each individual institution.

Initial Data from Phase 2 Trial of Vigil in Ewing’s sarcoma presented at 2018 COG

As of October 5, 2018, eight patients were enrolled in the Part 2 of the trial, and five patients are still alive. Two patients experienced RECIST partial response and retrospectively confirmed histological complete response. Four patients had durable stable disease as best response for ≥6 months.

All eight patients had histologically confirmed Ewing’s Sarcoma. The mean age was 24 years (range: 12-46 years). All patients were heavily pretreated and failed treatment with Temozolomide and Irinotecan previously, with a mean of 5 lines of systemic treatments prior to study enrollment.

Historical progression-free survival for patients in second relapse (or greater) Ewing’s Sarcoma is 3 months or less. The median progression-free survival of the patients enrolled was 8.2 months.

The combination of Vigil, Irinotecan and Temozolomide in third-line or greater Ewing’s Sarcoma demonstrated favorable safety profile with limited treatment-related toxicities.

Phase 2 data demonstrates similar results from Phase 1 trial

Previously published data of patients in second relapse (or greater) Ewing’s Sarcoma enrolled and treated with Vigil monotherapy on a Phase 1 study revealed clinical benefit with a median survival of 2 years. While the median OS of patients in the Phase 2 study, treated with the combination of Vigil, Irinotecan, and Temozolomide has not been reached, favorable event-free survival has been observed.

Phase 1 and 2 data supports Phase 3 VITA Study

“Phase 1 and 2 data justifies safety and evidence of patient clinical benefit with Vigil to advance to Phase III registration trial of Vigil / Irinotecan / Temozolomide in in first relapse Ewing’s SarcomA compared to Temozolomide / Irinotecan,” said Dr. John Nemunaitis, Chief Medical Officer of Gradalis.  “In aggregate, these data presented at COG demonstrate Gradalis’ approach of exploiting the patient's existing, highly-adapted immune system by presenting the entire tumor neoantigen matrix and inducing T-cell responses against their cancer has great promise.”

For more information about these clinical trials, please visit https://clinicaltrials.gov/ct2/show/NCT03495921.

About Vigil

Vigil is a proprietary, investigational cellular immunotherapy technology that combines genetic engineering with the science of immuno-oncology.  Vigil is intended to stimulate and enhance the body’s natural mechanism for recognizing and killing cancer cells. It utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy. By utilizing the patient's own tumor as the antigen source, Vigil is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient's unique tumor antigens.  Vigil is being studied in Ewing's sarcoma, in gynecological cancer and advanced women’s cancer in combination with PD-L1 inhibitors, and ovarian cancer as a single agent.

About Gradalis, Inc.

Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.

For additional information, please visit https://www.gradalisinc.com

Forward-Looking Statements 

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Gradalis cautions investors not to rely too heavily on the forward-looking statements the company makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Gradalis undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media and Investor Inquiries:

Walter Chen

Vice President – Corporate Development

Gradalis, Inc.

214-442-8100

wchen@gradalisinc.com

GradalisLogo_nograd.png

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Nov
DANSKE
Jeg vil gerne opfordrer jer til at kikke på 6212 indlæg omkring Danske Bank - min oplevelse er at ha..
52
13 Nov
 
Hvis jeg må være så fri at komme med en opfordring til de ansvarlige for dette forum. I skulle prøve..
31
11 Nov
 
Hej,   Jeg lægger kvartals regnskabs-tal ind for samtlige Nordiske selskaber fra Nasdaq OMX og Oslo ..
20
11 Nov
NOVO-B
Novo, Lilly, Sanofi og alle de andre diabetes-butikker er kommet med regnskab. AstraZeneca var den s..
20
14 Nov
CHEMM
Jeg har det lidt som vagabonderne Vladimir og Estragon i Samuel Becketts skuespil,hvor de 2 sidder u..
19
12 Nov
I:NDX
Du virker ret let påvirkelig i dine holdninger, senest:   24/10-18:Sælg nu for pokker. Bear market. ..
19
11 Nov
DANSKE
Det er muligt du syntes det - 6212 er langt langt over stregen......👎
19
11 Nov
DANSKE
Giver dig helt ret 6212 er meget trættende at læse Og jeg forstår ikke hans indlæg ikke bliver slet..
17
15 Nov
VELO
Lidt tanker omkring Velos prissætning og hvorfor jeg stadig finder den absurd undervurderet: De h..
16
10 Nov
NOVO-B
Han er den mest kompetente herinde. Så er lidt ærgerligt at du må den måde sænker / ødelægger forrum..
16

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FSIS Recall Release 112-2018 Salmonella
2
Gulf Island Completes Sale of Texas North Yard
3
SUEZ FILES INTENT TO ACQUIRE EAGLE WATER IN IDAHO
4
FinTech Acquisition Corp. III Announces Pricing of Upsized $300,000,000 Initial Public Offering
5
Laureate Education Announces Pricing of Public Offering by Selling Stockholder

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 November 2018 20:49:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181114.1 - EUROWEB5 - 2018-11-16 21:49:14 - 2018-11-16 20:49:14 - 1000 - Website: OKAY